Checkpoint Inhibitors in Head and Neck Cancer

July 7th 2017

Expert Perspective on Treatment of Polycythemia Vera

May 31st 2017

Managing Chemotherapy Toxicity for 5-FU and Capecitabine

May 30th 2017

Current Approaches in Advanced Non-Driver Lung Adenocarcinoma

May 12th 2017

New Treatment Regimens for Previously Treated Myeloma

April 28th 2017

Next-Generation Agents for ALK-Positive NSCLC

April 27th 2017

Molecular Testing and EGFR-Mutant Non-Small Cell Lung Cancer

April 24th 2017

Targeting Angiogenesis with Chemotherapy for Advanced Breast Cancer

April 19th 2017

Practical Guide on the Use of Immunotherapy in Melanoma

February 8th 2017

Treatment of ALK- or ROS1-Mutated Non-Small Cell Lung Cancer

January 31st 2017

TKI-Resistant Chronic Myeloid Leukemia

January 21st 2017

Acute Promyelocytic Leukemia (APL): Diagnosis and Treatment

January 17th 2017

Chronic Myeloid Leukemia: Refining the Use of BCR-ABL TKIs

January 13th 2017

The Era of Immunotherapy for Advanced Head & Neck Cancer Squamous Cell Carcinoma

December 22nd 2016

Precision Medicine in BRAF-Mutated Non–Small Cell Lung Cancer

December 22nd 2016

Novel Treatment Approaches in Glioblastoma

December 21st 2016

EGFR-Targeted Therapy for NSCLC: Tolerability-Guided Dose Adjustment

December 17th 2016

Improving Prostate Cancer Outcomes: A Model for Shared Care

December 7th 2016

The Emerging Role of FLT3 Inhibitors in AML and ASM

December 1st 2016

Global Insights on Anti-Angiogenic Therapy for Metastatic Lung Cancer

November 11th 2016